Related Experiment Video
Updated: Oct 16, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Stratification Analysis of Statin Effect on Major Adverse Cardiac Events After Percutaneous Coronary Intervention in
Takeo Horikoshi1, Takamitsu Nakamura1, Toru Yoshizaki1
1Department of Internal Medicine II, University of Yamanashi, Faculty of Medicine, Yamanashi, Japan.
Insights
Statin therapy may benefit hemodialysis patients with coronary artery disease after percutaneous coronary intervention. Stratification identified specific patient factors, including male sex and diabetes, associated with reduced major adverse cardiac events.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Statin use in hemodialysis patients for cardiovascular event reduction is controversial.
- Previous studies have not consistently shown benefits of statins in this population.
- Identifying specific patient subgroups who benefit from statins is crucial for secondary prevention.
Purpose of the Study:
- To investigate the effectiveness of statin therapy for secondary prevention in hemodialysis patients with coronary artery disease.
- To identify clinical factors associated with beneficial statin effects in this high-risk group.
- To examine the impact of statins on major adverse cardiac events (MACEs) after percutaneous coronary intervention.
Main Methods:
- Prospective, multicenter study of 234 hemodialysis patients with coronary artery disease undergoing percutaneous coronary intervention.
- Follow-up for up to 3 years to monitor MACEs (all-cause death, nonfatal myocardial infarction).
- Inverse probability of treatment weighting adjustment for bias reduction and stratification analysis to identify influencing factors.
Main Results:
- Statin therapy was associated with a significantly reduced rate of MACEs (adjusted hazard ratio 0.30).
- Patients experiencing MACEs had significantly lower statin use.
- Beneficial statin effects were linked to factors including male sex, older age, lower BMI, hypertension, diabetes, higher CRP, heart failure, reduced LV function, non-ACS, and shorter stent length.
Conclusions:
- Statin therapy is effective for preventing MACEs in hemodialysis patients post-percutaneous coronary intervention.
- Specific clinical factors predict statin effectiveness, enabling personalized secondary prevention strategies.
- Further research into statin's role in hemodialysis patients with identified clinical characteristics is warranted.
Abstract:
The statin use in patients on hemodialysis remains controversial, and no beneficial effects of statin on the reduction of adverse cardiovascular events have been reported in these patients. This study used stratification analysis to examine the clinical factors in patients on hemodialysis who could benefit from statin for secondary prevention. This prospective multicenter study included 234 consecutive patients on hemodialysis with coronary artery disease who underwent successful reperfusion therapy with percutaneous coronary intervention. The patients were followed up for up to 3 years or until the occurrence of major adverse cardiac events (MACEs; defined as a composite of all-cause death and nonfatal myocardial infarction). Inverse probability of treatment weighting adjustment was used to remove the selection bias. During the median follow-up period of 30 months, MACEs occurred in 55 patients. Patients with MACEs had significantly lower statin therapy (P < 0.001). Multivariable Cox proportional hazards analysis showed that the patients on statins had a significantly reduced rate of MACE occurrence [adjusted hazard ratio 0.30 (0.11-0.81), P = 0.02]. The stratification analysis of outcomes according to the presence of clinical factors showed that beneficial effects of statin were associated with man, elderly, lower body mass index, lower abdominal circumference, hypertension, diabetes, higher C-reactive protein, symptomatic heart failure, lower left ventricular function, nonacute coronary syndrome, and shorter stent length. Statin was effective for the prevention of MACEs in patients on hemodialysis who underwent percutaneous coronary intervention. We identified specific clinical factors affecting statin effectiveness for secondary prevention.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Coronary Artery Disease IV: Preventive Measures